SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Directorate Change

16 Mar 2023 07:05

RNS Number : 1563T
Rentokil Initial PLC
16 March 2023
Β 

16 March 2023

Β 

Directorate Changes including Appointment of Non-Executive Director

Β 

Rentokil Initial plc (FTSE: RTO, "the Company") today announces the appointment of Sally Johnson to its Board as a Non-Executive Director with effect from 1 April 2023. Sally will also become a member of the Nomination Committee and Audit Committee from this date.

Β 

Sally brings to the Board substantial commercial and strategic finance experience from her extensive executive career. Sally is the Chief Financial Officer of the FTSE 100 company Pearson plc, which is also listed on the New York Stock Exchange. Since joining Pearson in 2000 she has held various finance and operations roles across The Penguin Group, the education business and at a corporate level at Pearson. She was also a Trustee for the Pearson Pension Plan from 2012 to 2018. Sally is a member of the Institute of Chartered Accountants in England and Wales and completed her training at PricewaterhouseCoopers.

Β 

Julie Southern, Non-Executive Director, member of the Nomination Committee and Remuneration Committee and Chair of the Audit Committee, has informed the Company that, having served on the Board for almost nine years and in line with best practice, she does not intend to stand for re-election at the Company's AGM on 10 May 2023 and will, therefore, retire as a director of the Company from the conclusion of that meeting. The Company is pleased to announce that Sally Johnson will succeed Julie as Chair of the Audit Committee from this date.

Β 

Commenting on the changes to the Board, Richard Solomons, Chairman of Rentokil Initial, said: "We are delighted to welcome Sally to the Board of Rentokil Initial. Sally is an experienced finance executive and her international knowledge and business acumen will be an asset to the Board. I would like to thank Julie for her very significant contribution to the Board and to the success of the Company since she joined us in 2014, in particular in her work as Chair of the Audit Committee."Β 

Β 

There are no further details to be disclosed relating to Sally Johnson under Section 9.6.13 of the Listing Rules.

Β 

Β 

For further information please contact:

Β 

Rentokil Initial plc

Β 

Media

Malcolm Padley

07788 978199

Company Secretary

Catherine Stead

07826 533700

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BOAGPUWPWUPWUGQ
Date   Source Headline
21st May 20267:00 amRNSAppointment of CEO, North America
8th May 202610:30 amRNSHolding(s) in Company
7th May 20264:40 pmRNSResult of AGM
23rd Apr 20264:25 pmRNSFinal Dividend – Pence Sterling Amount Payable
23rd Apr 20262:30 pmRNSIssuance of $500 million 4.625% Notes due 2031
21st Apr 202610:30 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSQ1 Trading Update
15th Apr 20267:00 amRNSDirectorate Change
30th Mar 202610:30 amRNSHolding(s) in Company
26th Mar 20263:46 pmRNSDirector/PDMR Shareholding
25th Mar 202610:50 amRNSAnnual Financial Report
17th Mar 20264:30 pmRNSDirector/PDMR Shareholding
16th Mar 202610:32 amRNSHolding(s) in Company
16th Mar 202610:32 amRNSHolding(s) in Company
12th Mar 202610:30 amRNSHolding(s) in Company
10th Mar 20264:28 pmRNSDirector/PDMR Shareholding
10th Mar 20264:28 pmRNSDirector/PDMR Shareholding
10th Mar 20264:26 pmRNSDirector/PDMR Shareholding
10th Mar 20264:26 pmRNSDirector/PDMR Shareholding
9th Mar 202611:15 amRNSHolding(s) in Company
5th Mar 20267:00 amRNSPreliminary Results
5th Mar 20267:00 amRNSChair Succession Planning Update
23rd Feb 202610:30 amRNSHolding(s) in Company
19th Feb 20262:50 pmRNSDirector Declaration
12th Feb 20265:30 pmRNSNotice of Early Redemption
20th Jan 202610:25 amRNSHolding(s) in Company
19th Jan 202610:30 amRNSHolding(s) in Company
16th Jan 20263:00 pmRNSHolding(s) in Company
14th Jan 202610:30 amRNSHolding(s) in Company
13th Jan 202610:30 amRNSHolding(s) in Company
13th Jan 20267:00 amRNSDirectorate change
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
5th Dec 202510:30 amRNSHolding(s) in Company
5th Dec 202510:30 amRNSHolding(s) in Company
26th Nov 20254:25 pmRNSHolding(s) in Company
28th Oct 202510:45 amRNSHolding(s) in Company
28th Oct 202510:45 amRNSHolding(s) in Company
27th Oct 202510:30 amRNSHolding(s) in Company
23rd Oct 202511:45 amRNSHolding(s) in Company
23rd Oct 20257:00 amRNSQ3 Trading Update
21st Oct 202510:00 amRNSHolding(s) in Company
14th Oct 202510:00 amRNSHolding(s) in Company
1st Oct 202510:30 amRNSBlock listing Interim Review
30th Sep 202510:30 amRNSCompletion of France Workwear business sale
25th Sep 20254:15 pmRNSDirector/PDMR Shareholding
24th Sep 20256:00 pmRNSDirector Declaration
26th Aug 202512:30 pmRNSInterim Dividend – Pence Sterling Amount Payable
7th Aug 202511:10 amRNSHolding(s) in Company
31st Jul 20257:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.